NCT05790694 is a Phase 1 clinical trial of HBM9378 (SKB378) Injection in Asthma, sponsored by Harbour BioMed (Guangzhou) Co. Ltd..

Who is sponsoring NCT05790694?

NCT05790694 is sponsored by Harbour BioMed (Guangzhou) Co. Ltd..

What drugs are being tested in NCT05790694?

Interventions in NCT05790694: HBM9378 (SKB378) Injection, Placebo.

Is NCT05790694 still recruiting?

NCT05790694 is currently status unknown. Last updated 30 March 2023.

Last reviewed 2023-03-30 · How we verify

NCT05790694

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial of HBM9378 in Healthy Chinese Subjects

Status unknown Phase 1 Last updated 30 March 2023

What this trial tests

Phase 1 trial testing HBM9378 (SKB378) Injection in Asthma in 50 participants. Status unknown.

Timeline

26 August 2022

Primary endpoint
22 September 2023

22 September 2023

Quick facts

Lead sponsor	Harbour BioMed (Guangzhou) Co. Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	26 August 2022
Primary completion	22 September 2023
Estimated completion	22 September 2023
Sites	1 location across China

Drugs / interventions tested

HBM9378 (SKB378) Injection — full drug profile →
Placebo

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

Harbour BioMed (Guangzhou) Co. Ltd. — full company profile →

Who can join

Adults 18 to 50, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective is to evaluate the safety, tolerability and pharmacokinetic profile of a single subcutaneous injection of HBM9378 (SKB378) at different doses in healthy Chinese subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety, Tolerability, and Pharmacokinetics of HBM9378 (SKB378/WIN378), a Fully Human IgG1 Monoclonal Antibody Against TSLP After Single Ascending Doses in Chinese Healthy Subjects.
Yang X, Xu M, Cao N, Zhao S, et al · · 2026 · PMID 41873335 · DOI 10.2147/dddt.s538649

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Harbour BioMed (Guangzhou) Co. Ltd. trials

Trials by the same sponsor.

NCT05332210 — Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis · Phase 3 · unknown
NCT05167071 — HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study · Phase 1 · active not recruiting
NCT05149027 — A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients · Phase 1 · unknown
NCT05039190 — Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients · Phase 3 · completed
NCT04633213 — A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye · Phase 3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05790694 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Harbour BioMed (Guangzhou) Co. Ltd.
Last refreshed: 30 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05790694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing